IAMA Therapeutics

📅 We are excited to be part of the 37th ECNP Congress, 21-24 September 2024, in Milan! 🧠 Join us to learn more about IAMA Therapeutics' advancements in developing NKCC1 inhibitors for treating neurological disorders at Posters P2267, P2268, P2271 on 23/09/24, 12:35 - 14:00. 🔗 Check out the full programme here: https://lnkd.in/ecfX9Wfz and meet the team | Federico Bolognani, MD, PhD Laura Cancedda Annalisa Savardi Paolo Vigo 👋 Looking forward to seeing you! #ECNP2024 #Neuroscience #Biotech #IAMATherapeutics

IAMA is at #FENS2024! Yesterday, our Founder Laura Cancedda shared insights into the latest research activities from her lab at the Istituto Italiano di Tecnologia, and today our Head of Neuropharmacology Annalisa Savardi presented the preclinical package of our lead compound IAMA-6 in a poster session! We’re thrilled to see such tremendous attendance from all over the world, providing a fantastic opportunity for sharing knowledge and fostering new collaborations. If you want to reach out to us, we’ll be in Vienna until Saturday! #Innovation #Neuroscience #IAMAtherapeutics

We are excited to announce the appointment of Federico Bolognani, MD, PhD, as our Chief Medical Officer (CMO). With his extensive expertise in clinical development and translational medicine, Dr. Bolognani joins our team to lead the advancement of therapeutic solutions for patients affected by neurodevelopmental disorders, epilepsy, and cognitive impairments.   Dr. Federico Bolognani brings over 15 years of experience in Drug Development, with a focus on the Biotechnology sector. He has led clinical programs that successfully delivered clinical trial results, contributing to the acquisition of two companies by larger pharmaceutical entities. He is also a member of the Scientific Board of diverse Patient Advocacy groups and Foundations in Neurodevelopmental disorders.   Learn more about IAMA Therapeutics and our team: https://lnkd.in/djucuMec   #IAMAtherapeutics #Neuroscience #DrugDiscovery

Today is World Autism Awareness Day, a moment to recognize and embrace neurodiversity. At IAMA Therapeutics, we're committed to advancing treatments for individuals with neurodevelopmental disorders, including autism spectrum disorder (ASD). Autism is a spectrum disorder, and each individual's journey is unique. This World Autism Awareness Day, let's celebrate the strengths and perspectives of individuals with autism, while also advocating for greater understanding and acceptance. With our lead compound, IAMA-6, we're developing therapeutics solutions to address the unique challenges faced by individuals with ASD. By targeting cation-chloride cotransporters, we aim to restore neuronal excitability and offer hope to those affected by autism. Our team is dedicated to making a difference in the lives of those living with autism and other neurodevelopmental conditions. Together, let's work towards a future where everyone, regardless of their neurology, is valued and supported. #WorldAutismAwarenessDay #Autism #IAMAtherapeutics

IAMA Therapeutics will be attending BIO-Europe Spring in Barcelona, Spain, from March 18th to 20th, 2024! It's an incredible opportunity for us to connect with industry leaders and investors, explore potential collaborations, and discuss our platform targeting chloride cotransporters to treat brain disorders. See you in Barcelona! #BIOEuropeSpring #IAMAtherapeutics #Biotech #Neuroscience

Exciting News! We're thrilled to announce that we've initiated our First-in-Human Clinical Trial for the treatment of neurodevelopmental disorders. In this landmark achievement, we've successfully dosed the first two cohorts of subjects and we are moving forward to the third one in a first-in-human Phase 1 clinical trial of IAMA-6, our promising small molecule designed to target NKCC1. IAMA-6 is our lead clinical program, representing a breakthrough in addressing neurodevelopmental disorders. This highly selective small molecule, designed for oral administration, targets NKCC1-associated neuronal hyperexcitability. Preclinical studies have demonstrated its safety and efficacy, paving the way for its evaluation in a Phase 1 clinical trial. The therapeutic potential of IAMA-6 extends to a spectrum of neurodevelopmental disorders, including epilepsy and other central nervous system disorders, offering hope for patients and families affected by these conditions. Learn more about our mission at https://lnkd.in/d7ayaMWE #IAMAtherapeutics #Neurodevelopment #ClinicalTrial #Neuroscience #Biotech

IAMA Therapeutics is excited to be onsite at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco this week. #JPM2024 #Biotech #Neuroscience #Epilepsy #Autism #Neurodevelopment #Investment #Partnering #Dealmaking

Today IAMA Therapeutics announced that the Italian Medicines Agency (AIFA Agenzia Italiana del farmaco) approved a Clinical Trial Application (CTA) to begin a Phase 1 Study of IAMA-6 for the treatment of autism and epilepsy. Read more: https://bit.ly/3TyvH5X   #Biotech #LifeScience #Neuroscience #Epilepsy #Autism #Neurodevelopment

IAMA Therapeutics is presenting new preclinical results that support the potential for IAMA-6 as a disease-modifying therapy for drug-resistant epilepsies at the American Epilepsy Society (AES) 2023 Annual Meeting. Read more: https://bit.ly/3T8yYbU   #AES2023 #Biotech #LifeScience #Neuroscience #Epilepsy #Neurodevelopment

November is National Family Caregivers Month in the United States. We want to take the time to honor the dedication of those family members who provide essential care and support to their loved ones affected by pediatric central nervous system disorders and more. #Biotech #LifeScience #Neuroscience #Neurodevelopment #Epilepsy #Autism #RareDisease